# Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer

> **NCT03193814** · PHASE2 · WITHDRAWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology**

## Conditions studied

- Colorectal Cancer
- Chemotherapy
- Angiogenesis

## Interventions

- **DRUG:** Chemotherapy + Apatinib

## Key facts

- **NCT ID:** NCT03193814
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate patient enrollment
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193814, "Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03193814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*